Research programme: haemophilia A stem cell therapy - Opus Bio

Drug Profile

Research programme: haemophilia A stem cell therapy - Opus Bio

Alternative Names: LG 889

Latest Information Update: 30 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lentigen Corporation
  • Developer Expression Therapeutics; Opus Bio
  • Class Stem cell therapies
  • Mechanism of Action Blood coagulation factor replacements; Cell replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 30 Dec 2014 9167038, 9167065 - corrected organisational relationships; changed owner to opus bio.
  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
  • 14 Aug 2014 Miltenyi Biotec acquires the cell and gene therapy assets of Lentigen Corporation, and forms Lentigen Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top